CC BY 4.0 · Synlett
DOI: 10.1055/a-2564-4920
letter

A Diastereoselective Mizoroki–Heck Reaction for Synthesis of Spirooxindole-Based Nonnatural Amino Acids Using a Boc-Protected Amine Chiral Auxiliary

Jens Lindman
a   Department of Medicinal Chemistry, Uppsala University, Husargatan 3, 751 23 Uppsala, Sweden
,
Sharathna Puthiyaparambath
a   Department of Medicinal Chemistry, Uppsala University, Husargatan 3, 751 23 Uppsala, Sweden
,
b   The Beijer Laboratory, Science for Life Laboratory, Department of Medicinal Chemistry, Uppsala University, BMC, P.O. Box 574, 751 23 Uppsala, Sweden
c   Nanotechnology and Functional Materials, Department of Materials Science and Engineering, Ångström Laboratory, Uppsala University, Lägerhyddsvägen 1, 751 03 Uppsala, Sweden
,
a   Department of Medicinal Chemistry, Uppsala University, Husargatan 3, 751 23 Uppsala, Sweden
,
b   The Beijer Laboratory, Science for Life Laboratory, Department of Medicinal Chemistry, Uppsala University, BMC, P.O. Box 574, 751 23 Uppsala, Sweden
› Institutsangaben

We thank Uppsala University and the Kjell and Märta Beijer Foundation for their support.
 


Abstract

Nonnatural amino acids are pivotal for expanding the functional diversity of peptides and proteins, enabling novel therapeutic opportunities. Mono-Boc-protected spirocyclization precursors have been developed as versatile intermediates for the diastereoselective synthesis of spirooxindole-based nonnatural amino acids by the Mizoroki–Heck reaction. Catalytic hydrogenation produced cyclopentyl derivatives, expanding the diversity of these amino acids. Furthermore, one spirooxindole derivative was incorporated into a tripeptide by solid-phase peptide synthesis on Rink amide resin to demonstrate its potential in peptide modification and drug development.


#

The Mizoroki–Heck reaction is a fundamental method for carbon–carbon (C-C) bond formation, and is highly valued for its ability to construct complex molecular structures with precision and efficiency.[1] [2] [3] [4] Its utility in creating biologically active molecules, natural products, and stereochemically defined frameworks highlights its indispensability in medicinal chemistry and synthetic innovation. The intramolecular Mizoroki–Heck reaction enables efficient cyclization of alkenes and aryl/vinyl halides, to form stereodefined five- or six-membered rings.[1,2] Key stereoselectivity is controlled by ligands, substrate design, reaction conditions, and chiral catalysts. This method is vital for synthesizing complex cyclic molecules, introducing stereocenters, and accessing enantioenriched compounds, with broad applications in pharmaceuticals, natural products, and material science.[3,4]

As part of a medicinal chemistry program aimed at the synthesis of nonnatural γ-amino acids, our group reported a stereoselective functionalization of derivatives of 2-azabicyclo[2.2.1]hept-5-en-3-one (Vince lactam),[5] a common starting material for the synthesis of the carbocyclic nucleoside class of antivirals (Scheme [1]). We surmised that the use of a bulky amine protecting group as a chiral auxiliary might control the diastereoselectivity of a Mizoroki–Heck arylation and vinylation of the cyclopentenyl scaffold, producing nonnatural γ-amino acids with protecting groups on both the C- and N-terminals. Spirooxindoles are prominent structural motifs found in a wide range of natural products and synthetic compounds with significant biological activities.[6] [7] Additionally, their role in asymmetric synthesis and chiral catalyst design highlights their broad utility in advancing chemical and medicinal research.[8]

Solid-phase peptide synthesis (SPPS) is a widely used technique for synthesizing peptides both on a laboratory scale and in industrial applications.[9] [10] It involves anchoring an N-protected amino acid to a solid phase, sequentially coupling additional amino acids using amide reagents, and cleaving the resulting peptide from the resin. Because the deprotection of 2,5-dimethylpyrrole-protected amines previously used as chiral auxiliaries[11] requires conditions that are incompatible with SPPS, replacing this protecting group with an alternative that could be deprotected under the typically milder conditions employed in SPPS was investigated. In a previously reported study in which we examined the directing effect of the 2,5-dimethylpyrrole moiety on the intermolecular Mizoroki–Heck reaction,[12] we also assessed the ability of mono- and di-Boc-protected amines to influence the diastereoselectivity of the reaction.[13] Whereas the reaction between a vinyl bromide and mono-Boc-protected derivatives gave 1:1 mixtures of diastereomers, the di-Boc-protected derivatives provided >98:2 diastereoselectivity, albeit with lower isolated product yields than the corresponding 2,5-dimethylpyrrole-protected substrates (Scheme [2]).

As the preparation of Boc-protected amines is relatively easy and the intermolecular Mizoroki–Heck reaction shown in Scheme [2] provided the product, a method for the intramolecular Mizoroki–Heck synthesis of spirooxindoles bearing Boc protecting groups on the cyclopentenyl amine was investigated. Here, we report a highly stereoselective method for producing spirooxindole-based nonnatural amino acids primed for SPPS applications.

Zoom Image
Scheme 1 Diastereoselective synthesis of Vince lactam-derived cyclopentenyl γ-amino acids, and some potent biologically active spirooxindole derivatives (Wetzel et al.)[8] PG: protecting group.
Zoom Image
Scheme 2 The influence of mono-Boc, di-Boc, and 2,5-dimethylpyrrole protection of a chiral amine on the diastereoselectivity of a Mizoroki–Heck reaction. Reagents and conditions: (i) Pd(OAc)2 (10 mol%), NaHCO3 (2.5 equiv), TBACl (1.1 equiv), DMF, 90 °C, 36 h.

The di-Boc-protected substrate 13a was synthesized as we previously described.[8] Ester hydrolysis of acrylate 13a using LiOH in a mixture of THF and water produced 14a, which was directly converted into the corresponding acid chloride 15a using thionyl chloride with a catalytic amount of DMF (Scheme [3]). The crude product was treated with methyl 3-amino-4-bromobenzoate that had been preactivated with sodium hydride. The di-Boc-protected amine displayed a poor stability under these conditions, with the mono-Boc-protected 16a being the major product rather than the desired di-Boc derivative, which was not isolated. The mono-Boc substrate 16a was subjected to the Mizoroki–Heck spirocyclization protocol for the synthesis of spirooxindoles previously described by Roy et al.,[14] producing 17a as a single diastereomer in 71% isolated yield. This directing ability of the mono-Boc-protected amine in the cyclization was surprising, as di-Boc-protected amines were required to achieve diastereoselectivity in the intermolecular Mizoroki–Heck application shown in Scheme [2]. The difference might be a consequence of increased steric interactions in the intramolecular reaction.

Zoom Image
Scheme 3 Synthesis of the spirooxindole-based nonnatural amino acid 17a with protecting groups on both the N- and C-terminals. Reagents and conditions: (i) LiOH (5 equiv), 3:1 THF–H2O, 50 °C, overnight. (ii) SOCl2 (1.2 equiv), pyridine (1.1 equiv), DMF (cat.), CH2Cl2, 50 °C, 3 h. (iii) methyl 3-amino-4-bromobenzoate (1.5 equiv), NaH (2 equiv), THF, 50 °C, overnight, 54% (two steps). (iv) Pd(OAc)2 (5 mol%), 1,1′-bis(diphenylphosphino)ferrocene (dppf; 10 mol%), Et3N (2 equiv), DMF, 80 °C, 6 h, 71%

Due to its ability to retain the excellent diastereoselectivity of the spirocyclization reaction with the mono-Boc-protected amine, this synthetic route was adapted to start from the mono-Boc substrate 13b (Scheme [4]). By varying the position of the ester on the aniline, three spirocyclization precursors 16bf were prepared in moderate yields. These were subsequently subjected to the Mizoroki–Heck cyclization reaction, producing 17b,c,e,f in isolated yields of 75, 74, 76, and 66%, respectively. Precursors 16d and 16g did not react under these conditions, presumably due to steric crowding at the reactive aryl bromide center.

Zoom Image
Scheme 4 Synthesis of spirooxindoles 17b,c and 17e,f. Reagents and conditions: (i) LiOH (5 equiv), 3:1 THF–H2O, 50 °C, overnight. (ii) SOCl2 (1.2 equiv), pyridine (1.1 equiv), DMF (cat.), THF, 50 °C, 3 h. (iii) aniline (1.5 equiv), NaH (2 equiv), THF, 50 °C, overnight, 18–40% (two steps). (iv) Pd(OAc)2 (5 mol%), dppf (10 mol%), Et3N (2 equiv), DMF, 80 °C, 6 h.

The cyclopentenyl products were then reduced by hydrogenation using hydrogen gas (1 atm) with 10 mol% palladium on carbon[8] to give the saturated spirooxindole compounds 18ac and 18e,f in isolated yields of 84–98% (Scheme [5]). Moreover, the diastereomeric ratio remained unchanged after the hydrogenation process, confirming the robustness of the stereochemical outcomes under the applied reaction conditions.

Next, to determine the usefulness of the synthesized spirooxindole-based nonnatural amino acids, attempts were made to include one of these products in a tripeptide by SPPS on Rink amide resin (Scheme [6]). The synthesis of the tripeptide 20 was initiated by piperidine-mediated deprotection of the Rink amide Fmoc group, followed by coupling of Fmoc-protected phenylalanine through an Oxyma:DIC:DIPEA protocol. The same deprotection-coupling sequence was repeated for the coupling of 19, formed through ester hydrolysis of 17a with sodium carbonate in a mixture of acetonitrile and water at 100 °C under microwave heating.[16] As the Rink amide resin is acid-sensitive, this limits the possibilities of using strong acids for Boc deprotection. Thus, a method employing tin(IV) chloride in dichloromethane was used for the Boc deprotection.[15] Following this step, the final Fmoc-protected alanine was coupled by using the previously described coupling protocol. A small portion of the crude product was cleaved from the resin with TFA and analyzed by LC-UV/MS, where the expected mass of the product was successfully detected. However, a small amount of the spirooxindole–phenylalanine dipeptide was also observed, presumably due to incomplete Boc deprotection by tin(IV) chloride. Cleavage of the product from the resin, followed by precipitation in cold diethyl ether, provided the tripeptide product 20 in 86% yield. This initial experiment demonstrates that Boc-protected spirooxindole-based nonnatural amino acids are indeed compatible with SPPS, providing a viable pathway for incorporating our nonnatural amino acid scaffolds into peptides.

Zoom Image
Scheme 5 Hydrogenation of 17ac and 17e,f. Reagents and conditions: (i) Pd/C (10 mol%), pyridine (3 equiv), H2 (1 atm), 1:1 THF–EtOH.
Zoom Image
Scheme 6 Preparation of free acid 19 and synthesis of the spirooxindole-containing tripeptide 20 through SPPS on Rink amide resin

In conclusion, we have successfully prepared mono-Boc-protected spirocyclization precursors that provide a powerful approach for the diastereoselective synthesis of spirooxindole-based nonnatural amino acids, significantly enhancing the chemical diversity of available nonnatural amino acids.[17] The use of the Mizoroki–Heck cyclization, followed by catalytic hydrogenation permits the production of cyclopentyl derivatives, expanding the repertoire of nonnatural rigid amino acids. The incorporation of spirooxindoles into peptides through SPPS, demonstrated through the synthesis of a tripeptide on Rink amide resin, underscored the utility of this method in peptide modification and the creation of bioactive compounds of biological interest. This strategy holds great promise for advancing both peptide-based drug discovery and protein engineering.


#

Conflict of Interest

The authors declare no conflict of interest.

Supporting Information

  • References and Notes

  • 1 Yang J, Zhao H.-W, He J, Zhang C.-P. Catalysts 2018; 8: 23
  • 2 Berteina-Raboin S. Catalysts 2019; 9: 925
  • 3 Ping Y, Li Y, Zhu J, Kong W. Angew. Chem. Int. Ed. 2019; 58: 1562
  • 4 Beletskaya IP, Cheprakov AV. Chem. Rev. 2000; 100: 3009
  • 5 Singh R, Vince R. Chem. Rev. 2012; 112: 4642
  • 6 Saranya PV, Neetha M, Aneeja T, Anilkumar G. RSC Adv. 2021; 11: 7146
  • 7 Ye N, Chen H, Wold EA, Shi P.-Y, Zhou J. ACS Infect. Dis. 2016; 2: 382
  • 8 Panda SS, Girgis AS, Aziz MN, Bekheit MS. Molecules 2023; 28: 618
  • 9 Palomo JM. RSC Adv. 2014; 4: 32658
  • 10 Behrendt R, White P, Offer J. J. Pept. Sci. 2016; 22: 4
  • 11 Lindman J, Gopalan G, Palo-Nieto C, Brandt P, Gising J, Larhed M. ACS Omega 2022; 7: 32525
  • 12 Olofsson K, Larhed M, Hallberg A. J. Org. Chem. 1998; 63: 5076
  • 13 Wetzel A, Bergman J, Brandt P, Larhed M, Brånalt J. Org. Lett. 2017; 19: 1602
  • 14 Roy T, Brandt P, Wetzel A, Bergman J, Brånalt J, Sävmarker J, Larhed M. Org. Lett. 2017; 19: 2738
  • 15 Freeman NS, Gilon C. Synlett 2009; 2097
  • 16 Larhed M, Moberg C, Hallberg A. Acc. Chem. Res. 2002; 35: 717
  • 17 18a-c and 18e,f; General Procedure A 5 mL microwave vial was charged with the appropriate spirooxindole 17 (1 equiv) and Pd/C (10 mol%), and 1:1 THF–EtOH (1:1) was added to produce a 0.1 M solution. Pyridine (3 equiv) was then added and the mixture was stirred under H2 (1 atm) at r.t. for 24 h. H2O (5 mL) was added and the mixture was extracted with EtOAc (3 × 15 mL). The organic phase was washed with brine (5 mL), dried (MgSO4), filtered, and concentrated under reduced pressure. Methyl (1S,3R)-3-[(tert-Butoxycarbonyl)amino]-2′-oxo-1′,2′-dihydrospiro[cyclopentane-1,3′-indole]-6′-carboxylate (18a) Synthesized according to the general procedure and purified by flash chromatography (silica gel, 40% EtOAc–isohexane) as a white solid; yield: 32.0 mg (92%); [α]D 25 = 34.7 (c = 0.1, THF). 1H NMR (400 MHz, CDCl3): δ = 8.62 (s, 1 H), 7.77 (dd, J = 7.8, 1.3 Hz, 1 H), 7.56 (d, J = 1.3 Hz, 1 H), 7.24 (d, J = 7.8 Hz, 1 H), 5.85 (d, J = 8.9 Hz, 1 H), 4.51 (s, 1 H), 3.91 (s, 3 H), 2.39–2.19 (m, 3 H), 2.12–1.86 (m, 3 H), 1.46 (s, 9 H). 13C NMR (101 MHz, CDCl3): δ = 184.1, 166.7, 155.6, 141.3, 140.4, 130.1, 125.1, 122.5, 110.5, 79.4, 53.7, 53.1, 52.4, 44.3, 36.8, 34.7, 28.6. HRMS (ESI): m/z [M + H]+ calcd for C19H25N2O5: 361.1758; found: 361.1755.

Corresponding Author

Mats Larhed
Department of Medicinal Chemistry, Uppsala University
Husargatan 3, 751 23 Uppsala
Sweden   

Publikationsverlauf

Eingereicht: 21. Februar 2025

Angenommen nach Revision: 19. März 2025

Accepted Manuscript online:
21. März 2025

Artikel online veröffentlicht:
29. April 2025

© 2025. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by/4.0/)

Georg Thieme Verlag KG
Oswald-Hesse-Straße 50, 70469 Stuttgart, Germany

  • References and Notes

  • 1 Yang J, Zhao H.-W, He J, Zhang C.-P. Catalysts 2018; 8: 23
  • 2 Berteina-Raboin S. Catalysts 2019; 9: 925
  • 3 Ping Y, Li Y, Zhu J, Kong W. Angew. Chem. Int. Ed. 2019; 58: 1562
  • 4 Beletskaya IP, Cheprakov AV. Chem. Rev. 2000; 100: 3009
  • 5 Singh R, Vince R. Chem. Rev. 2012; 112: 4642
  • 6 Saranya PV, Neetha M, Aneeja T, Anilkumar G. RSC Adv. 2021; 11: 7146
  • 7 Ye N, Chen H, Wold EA, Shi P.-Y, Zhou J. ACS Infect. Dis. 2016; 2: 382
  • 8 Panda SS, Girgis AS, Aziz MN, Bekheit MS. Molecules 2023; 28: 618
  • 9 Palomo JM. RSC Adv. 2014; 4: 32658
  • 10 Behrendt R, White P, Offer J. J. Pept. Sci. 2016; 22: 4
  • 11 Lindman J, Gopalan G, Palo-Nieto C, Brandt P, Gising J, Larhed M. ACS Omega 2022; 7: 32525
  • 12 Olofsson K, Larhed M, Hallberg A. J. Org. Chem. 1998; 63: 5076
  • 13 Wetzel A, Bergman J, Brandt P, Larhed M, Brånalt J. Org. Lett. 2017; 19: 1602
  • 14 Roy T, Brandt P, Wetzel A, Bergman J, Brånalt J, Sävmarker J, Larhed M. Org. Lett. 2017; 19: 2738
  • 15 Freeman NS, Gilon C. Synlett 2009; 2097
  • 16 Larhed M, Moberg C, Hallberg A. Acc. Chem. Res. 2002; 35: 717
  • 17 18a-c and 18e,f; General Procedure A 5 mL microwave vial was charged with the appropriate spirooxindole 17 (1 equiv) and Pd/C (10 mol%), and 1:1 THF–EtOH (1:1) was added to produce a 0.1 M solution. Pyridine (3 equiv) was then added and the mixture was stirred under H2 (1 atm) at r.t. for 24 h. H2O (5 mL) was added and the mixture was extracted with EtOAc (3 × 15 mL). The organic phase was washed with brine (5 mL), dried (MgSO4), filtered, and concentrated under reduced pressure. Methyl (1S,3R)-3-[(tert-Butoxycarbonyl)amino]-2′-oxo-1′,2′-dihydrospiro[cyclopentane-1,3′-indole]-6′-carboxylate (18a) Synthesized according to the general procedure and purified by flash chromatography (silica gel, 40% EtOAc–isohexane) as a white solid; yield: 32.0 mg (92%); [α]D 25 = 34.7 (c = 0.1, THF). 1H NMR (400 MHz, CDCl3): δ = 8.62 (s, 1 H), 7.77 (dd, J = 7.8, 1.3 Hz, 1 H), 7.56 (d, J = 1.3 Hz, 1 H), 7.24 (d, J = 7.8 Hz, 1 H), 5.85 (d, J = 8.9 Hz, 1 H), 4.51 (s, 1 H), 3.91 (s, 3 H), 2.39–2.19 (m, 3 H), 2.12–1.86 (m, 3 H), 1.46 (s, 9 H). 13C NMR (101 MHz, CDCl3): δ = 184.1, 166.7, 155.6, 141.3, 140.4, 130.1, 125.1, 122.5, 110.5, 79.4, 53.7, 53.1, 52.4, 44.3, 36.8, 34.7, 28.6. HRMS (ESI): m/z [M + H]+ calcd for C19H25N2O5: 361.1758; found: 361.1755.

Zoom Image
Scheme 1 Diastereoselective synthesis of Vince lactam-derived cyclopentenyl γ-amino acids, and some potent biologically active spirooxindole derivatives (Wetzel et al.)[8] PG: protecting group.
Zoom Image
Scheme 2 The influence of mono-Boc, di-Boc, and 2,5-dimethylpyrrole protection of a chiral amine on the diastereoselectivity of a Mizoroki–Heck reaction. Reagents and conditions: (i) Pd(OAc)2 (10 mol%), NaHCO3 (2.5 equiv), TBACl (1.1 equiv), DMF, 90 °C, 36 h.
Zoom Image
Scheme 3 Synthesis of the spirooxindole-based nonnatural amino acid 17a with protecting groups on both the N- and C-terminals. Reagents and conditions: (i) LiOH (5 equiv), 3:1 THF–H2O, 50 °C, overnight. (ii) SOCl2 (1.2 equiv), pyridine (1.1 equiv), DMF (cat.), CH2Cl2, 50 °C, 3 h. (iii) methyl 3-amino-4-bromobenzoate (1.5 equiv), NaH (2 equiv), THF, 50 °C, overnight, 54% (two steps). (iv) Pd(OAc)2 (5 mol%), 1,1′-bis(diphenylphosphino)ferrocene (dppf; 10 mol%), Et3N (2 equiv), DMF, 80 °C, 6 h, 71%
Zoom Image
Scheme 4 Synthesis of spirooxindoles 17b,c and 17e,f. Reagents and conditions: (i) LiOH (5 equiv), 3:1 THF–H2O, 50 °C, overnight. (ii) SOCl2 (1.2 equiv), pyridine (1.1 equiv), DMF (cat.), THF, 50 °C, 3 h. (iii) aniline (1.5 equiv), NaH (2 equiv), THF, 50 °C, overnight, 18–40% (two steps). (iv) Pd(OAc)2 (5 mol%), dppf (10 mol%), Et3N (2 equiv), DMF, 80 °C, 6 h.
Zoom Image
Scheme 5 Hydrogenation of 17ac and 17e,f. Reagents and conditions: (i) Pd/C (10 mol%), pyridine (3 equiv), H2 (1 atm), 1:1 THF–EtOH.
Zoom Image
Scheme 6 Preparation of free acid 19 and synthesis of the spirooxindole-containing tripeptide 20 through SPPS on Rink amide resin